• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

    7/31/24 2:03:34 PM ET
    $NURO
    Medical/Dental Instruments
    Health Care
    Get the next $NURO alert in real time by email

    WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024.

    For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company's website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company's Investors section of the website.

    About NeuroMetrix

    NeuroMetrix is a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell® is a wearable neuromodulation platform. DPNCheck® is a point-of-care screening test for peripheral neuropathy. For more information, visit www.NeuroMetrix.com.

    NeuroMetrix, Inc.

    Thomas T. Higgins

    SVP and Chief Financial Officer

    [email protected]

    Source: NeuroMetrix, Inc.



    Primary Logo

    Get the next $NURO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NURO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NURO
    SEC Filings

    See more
    • SEC Form 15-12G filed by NeuroMetrix Inc.

      15-12G - NeuroMetrix, Inc. (0001289850) (Filer)

      5/12/25 4:05:30 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NeuroMetrix Inc.

      EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

      5/6/25 12:15:11 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NeuroMetrix Inc.

      EFFECT - NeuroMetrix, Inc. (0001289850) (Filer)

      5/6/25 12:15:15 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care

    $NURO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horowitz Joshua returned 90,307 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NeuroMetrix, Inc. (0001289850) (Issuer)

      5/5/25 6:51:59 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • Director Goodman David returned 7,602 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NeuroMetrix, Inc. (0001289850) (Issuer)

      5/5/25 5:53:03 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • Director Van Avermaete David returned 7,601 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NeuroMetrix, Inc. (0001289850) (Issuer)

      5/5/25 5:53:02 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care

    $NURO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

      ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

      5/2/25 8:00:00 AM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

      The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

      12/17/24 4:05:00 PM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • NeuroMetrix to be Acquired by electroCore

      WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. ("NeuroMetrix" or the "Company") (NASDAQ:NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. ("electroCore") (NASDAQ:ECOR), a commercial stage bioelectronic medicine and wellness company, will acquire NeuroMetrix. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. The shareholders of NeuroMetrix will be entitled to

      12/17/24 4:05:00 PM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments

    $NURO
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

      Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie

      4/19/24 8:00:00 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

      WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol

      9/1/22 9:00:00 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • NeuroMetrix Appoints Brad Fluegel to its Board of Directors

      WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha

      6/28/22 9:00:00 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care

    $NURO
    Financials

    Live finance-specific insights

    See more
    • electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

      The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

      12/17/24 4:05:00 PM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

      WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina

      8/6/24 7:00:00 AM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

      WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce

      7/31/24 2:03:34 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care

    $NURO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by NeuroMetrix Inc.

      SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)

      9/27/24 3:56:52 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by NeuroMetrix Inc. (Amendment)

      SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)

      3/4/24 4:12:13 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by NeuroMetrix Inc.

      SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)

      2/27/24 4:00:09 PM ET
      $NURO
      Medical/Dental Instruments
      Health Care